Win, Lose, or Draw? A Decade of Pharma Antitrust Since FTC vs. Actavis

In the Media
1 min read

Ten years ago, the US Supreme Court issued its 5-3 decision in FTC v. Actavis, which held that the rule of reason should govern so-called "pay-for-delay," or reverse payment, patent litigation settlement agreements between brand name and generic pharmaceutical manufacturers.

In a new episode of the American Bar Association's Our Curious Amalgam podcast, White & Case Antitrust partner Kristen O'Shaughnessy and associate Daniel Grossbaum speak about how the decision has shaped reverse-payment litigation and some of the key issues moving forward.

Press contact
For more information please speak to your local media contact.